Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: StockHawk who wrote (35432)	5/10/1999 10:43:00 AM
From: lindend	Respond to of 122087

FDA review posponed. Its FAR worse than that..postponement is ZONAs spin on the facts. This bad boy got REJECTED!!!!! And to think I was contemplating covering this trash! Pacific:ZNG) and Schering-Plough (NYSE:SGP - news) today announced that the companies have decided to forego a June FDA Advisory Panel review of the New Drug Application (NDA) for Vasomax® until the results of additional clinical studies being conducted by Schering-Plough can be submitted to the FDA. As a result of this decision, Zonagen expects that the FDA will issue a non-approvable letter for the NDA.